These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16150399)

  • 1. The role of biomarkers in the assessment of lupus.
    Merrill JT; Buyon JP
    Best Pract Res Clin Rheumatol; 2005 Oct; 19(5):709-26. PubMed ID: 16150399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in bringing the bench to bedside in drug development for SLE.
    Merrill JT; Erkan D; Buyon JP
    Nat Rev Drug Discov; 2004 Dec; 3(12):1036-46. PubMed ID: 15573102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokines and their receptors as biomarkers of systemic lupus erythematosus.
    Suh CH; Kim HA
    Expert Rev Mol Diagn; 2008 Mar; 8(2):189-98. PubMed ID: 18366305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for systemic lupus erythematosus.
    Herbst R; Liu Z; Jallal B; Yao Y
    Int J Rheum Dis; 2012 Oct; 15(5):433-44. PubMed ID: 23083033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How does one assess and monitor patients with systemic lupus erythematosus in daily clinical practice?
    Haq I; Isenberg DA
    Best Pract Res Clin Rheumatol; 2002 Apr; 16(2):181-94. PubMed ID: 12041948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus.
    Kuryliszyn-Moskal A; Klimiuk PA; Ciolkiewicz M; Sierakowski S
    J Rheumatol; 2008 Jul; 35(7):1307-13. PubMed ID: 18484695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic lupus erythematosus.
    Manson JJ; Rahman A
    Orphanet J Rare Dis; 2006 Mar; 1():6. PubMed ID: 16722594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations.
    Magalhães MB; da Silva LM; Voltarelli JC; Donadi EA; Louzada-Junior P
    Scand J Rheumatol; 2007; 36(6):442-7. PubMed ID: 18092265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New treatments for SLE: cell-depleting and anti-cytokine therapies.
    Anolik JH; Aringer M
    Best Pract Res Clin Rheumatol; 2005 Oct; 19(5):859-78. PubMed ID: 16150407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of vascular endothelial growth factor in children and adolescents with systemic lupus erythematosus.
    Heshmat NM; El-Kerdany TH
    Pediatr Allergy Immunol; 2007 Jun; 18(4):346-53. PubMed ID: 17346298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphopenia is associated with neuropsychiatric manifestations and disease activity in paediatric systemic lupus erythematosus patients.
    Yu HH; Wang LC; Lee JH; Lee CC; Yang YH; Chiang BL
    Rheumatology (Oxford); 2007 Sep; 46(9):1492-4. PubMed ID: 17673480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of flare on disease costs of patients with systemic lupus erythematosus.
    Zhu TY; Tam LS; Lee VW; Lee KK; Li EK
    Arthritis Rheum; 2009 Sep; 61(9):1159-67. PubMed ID: 19714597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum protein oxidation and apolipoprotein CIII levels in people with systemic lupus erythematosus with and without nephritis.
    Morgan PE; Sturgess AD; Hennessy A; Davies MJ
    Free Radic Res; 2007 Dec; 41(12):1301-12. PubMed ID: 17957542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus.
    Kümpers P; David S; Haubitz M; Hellpap J; Horn R; Bröcker V; Schiffer M; Haller H; Witte T
    Ann Rheum Dis; 2009 Oct; 68(10):1638-43. PubMed ID: 18930996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concentration of antibodies to extractable nuclear antigens and disease activity in systemic lupus erythematosus.
    Agarwal S; Harper J; Kiely PD
    Lupus; 2009 Apr; 18(5):407-12. PubMed ID: 19318392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging biological therapies in systemic lupus erythematosus.
    Mount GR; Gilliland WR
    Clin Pharmacol Ther; 2008 Jan; 83(1):167-71. PubMed ID: 18000515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis.
    Becker-Merok A; Kalaaji M; Haugbro K; Nikolaisen C; Nilsen K; Rekvig OP; Nossent JC
    Arthritis Res Ther; 2006; 8(6):R162. PubMed ID: 17062137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adrenomedullin--a potential disease activity marker and suppressor of nephritis activity in systemic lupus erythematosus.
    Mak A; Cheung BM; Mok CC; Leung R; Lau CS
    Rheumatology (Oxford); 2006 Oct; 45(10):1266-72. PubMed ID: 16595522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus erythematosus.
    Liu CC; Manzi S; Kao AH; Navratil JS; Ruffing MJ; Ahearn JM
    Arthritis Rheum; 2005 Oct; 52(10):3087-99. PubMed ID: 16200588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual.
    Vilá LM; Alarcón GS; McGwin G; Bastian HM; Fessler BJ; Reveille JD;
    Arthritis Rheum; 2006 Oct; 55(5):799-806. PubMed ID: 17013840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.